iRhythm Technologies Shares Preliminary Fourth Quarter 2024 Highlights and Business Update at the 43rd Annual J.P. Morgan Healthcare Conference
iRhythm Technologies (NASDAQ:IRTC) announced preliminary Q4 2024 operational highlights, expecting full-year 2024 revenue to exceed their previous guidance of $587.5 million. The company achieved record new account openings for both Zio monitor and Zio AT in Q4 2024, with strong contributions from national accounts.
Key developments include launching four healthcare systems on Epic Aura in Q4 2024, with broader U.S. rollout planned for 2025, and initiating Zio monitor home enrollment shipments. The company presented five studies at the American Heart Association, demonstrating Zio Monitor's effectiveness and patient satisfaction.
For 2025, iRhythm projects revenue between $675-685 million. The company expanded internationally into four European countries, received Japanese regulatory approval, and partnered with BioIntelliSense. Future focus includes expanding into primary care channels and enhancing quality systems.
iRhythm Technologies (NASDAQ:IRTC) ha annunciato i risultati preliminari delle operazioni del Q4 2024, prevedendo che i ricavi per l'intero anno 2024 supereranno la guida precedente di 587,5 milioni di dollari. L'azienda ha raggiunto un record di nuove aperture di account sia per il monitor Zio che per il Zio AT nel Q4 2024, con forti contributi da parte di account nazionali.
Sviluppi chiave includono il lancio di quattro sistemi sanitari su Epic Aura nel Q4 2024, con un'implementazione più ampia negli Stati Uniti pianificata per il 2025, e l'inizio delle spedizioni per l'iscrizione al monitor Zio a casa. L'azienda ha presentato cinque studi all'American Heart Association, dimostrando l'efficacia e la soddisfazione dei pazienti del monitor Zio.
Per il 2025, iRhythm prevede ricavi compresi tra 675-685 milioni di dollari. L'azienda si è espansa a livello internazionale in quattro paesi europei, ha ricevuto l'approvazione normativa giapponese e ha stretto una partnership con BioIntelliSense. Le future priorità includono l'espansione nei canali di assistenza primaria e il miglioramento dei sistemi di qualità.
iRhythm Technologies (NASDAQ:IRTC) anunció los resultados operativos preliminares del Q4 2024, pronosticando que los ingresos de todo el año 2024 superarán su guía anterior de 587,5 millones de dólares. La compañía logró un récord en la apertura de nuevas cuentas tanto para el monitor Zio como para el Zio AT en el Q4 2024, con fuertes contribuciones de cuentas nacionales.
Los desarrollos clave incluyen el lanzamiento de cuatro sistemas de salud en Epic Aura en el Q4 2024, con un despliegue más amplio en EE. UU. planeado para 2025, e iniciar los envíos de inscripción en casa para el monitor Zio. La empresa presentó cinco estudios en la Asociación Americana del Corazón, demostrando la efectividad y la satisfacción del paciente con el monitor Zio.
Para 2025, iRhythm proyecta ingresos entre 675-685 millones de dólares. La compañía se ha expandido internacionalmente a cuatro países europeos, recibió la aprobación regulatoria en Japón y se asoció con BioIntelliSense. Las futuras prioridades incluyen la expansión en los canales de atención primaria y la mejora de los sistemas de calidad.
iRhythm Technologies (NASDAQ:IRTC)는 2024년 4분기 운영 하이라이트를 발표하며 2024년 전체 수익이 5억 8천 7백 50만 달러에 대한 이전 지침을 초과할 것으로 예상하고 있습니다. 이 회사는 2024년 4분기 Zio 모니터와 Zio AT의 새로운 계좌 개설에서 기록을 세웠으며, 국가 계좌로부터 강력한 기여를 받았습니다.
주요 개발 사항으로는 2024년 4분기에 Epic Aura에서 4개의 헬스케어 시스템을 출시하고, 2025년에는 미국 전역으로 더 넓은 배포를 계획하고 있으며, Zio 모니터 재택 등록 발송을 시작하는 것입니다. 이 회사는 미국 심장 협회에서 5개의 연구를 발표하여 Zio 모니터의 효과성과 환자 만족도를 입증했습니다.
2025년을 위해 iRhythm은 6억 7천 5백만에서 6억 8천 5백만 달러 사이의 수익을 예상하고 있습니다. 이 회사는 4개 유럽 국가로 국제적으로 확장하였고 일본 규제 승인을 받았으며 BioIntelliSense와 파트너십을 맺었습니다. 앞으로의 초점은 1차 진료 채널로의 확장과 품질 시스템의 개선을 포함합니다.
iRhythm Technologies (NASDAQ:IRTC) a annoncé les points saillants opérationnels préliminaires du T4 2024, s'attendant à ce que le chiffre d'affaires annuel 2024 dépasse ses prévisions précédentes de 587,5 millions de dollars. L'entreprise a atteint un record d'ouvertures de nouveaux comptes pour le moniteur Zio et Zio AT au T4 2024, avec de fortes contributions provenant de comptes nationaux.
Les développements clés incluent le lancement de quatre systèmes de santé sur Epic Aura au T4 2024, avec un déploiement plus large prévu aux États-Unis pour 2025, et le début des expéditions d'inscription à domicile pour le moniteur Zio. L'entreprise a présenté cinq études lors de l'American Heart Association, démontrant l'efficacité du moniteur Zio et la satisfaction des patients.
Pour 2025, iRhythm prévoit un chiffre d'affaires compris entre 675-685 millions de dollars. L'entreprise s'est étendue à l'international dans quatre pays européens, a reçu l'approbation réglementaire japonaise et a noué un partenariat avec BioIntelliSense. Les futurs objectifs incluent l'expansion dans les canaux de soins primaires et l'amélioration des systèmes de qualité.
iRhythm Technologies (NASDAQ:IRTC) hat die vorläufigen operativen Höhepunkte des 4. Quartals 2024 bekannt gegeben und erwartet, dass der Umsatz für das Gesamtjahr 2024 die frühere Prognose von 587,5 Millionen US-Dollar übersteigen wird. Das Unternehmen erzielte im 4. Quartal 2024 einen Rekord an neuen Kontoeröffnungen sowohl für den Zio Monitor als auch für Zio AT, unterstützt durch starke Beiträge nationaler Konten.
Wichtige Entwicklungen umfassen den Launch von vier Gesundheitssystemen auf Epic Aura im 4. Quartal 2024, mit einer weiteren Ausweitung in den USA, die für 2025 geplant ist, sowie den Beginn der Heimregistrierung für den Zio Monitor. Das Unternehmen präsentierte fünf Studien bei der American Heart Association, die die Wirksamkeit und die Patientenzufriedenheit des Zio Monitors demonstrieren.
Für 2025 projiziert iRhythm Einnahmen zwischen 675-685 Millionen US-Dollar. Das Unternehmen hat international in vier europäische Länder expandiert, die regulatorische Genehmigung in Japan erhalten und eine Partnerschaft mit BioIntelliSense geschlossen. Zukünftige Schwerpunkte liegen in der Expansion in die Primärversorgungsbereiche und der Verbesserung der Qualitätssysteme.
- Full-year 2024 revenue expected to exceed previous guidance of $587.5 million
- Record quarter of new account openings for Zio monitor and Zio AT in Q4 2024
- Projected 2025 revenue of $675-685 million indicates strong growth
- International expansion into four European countries and Japanese market entry
- Successfully launched Epic Aura integration with four healthcare systems
- None.
Insights
The preliminary Q4 2024 update reveals strong operational momentum with revenue exceeding the
The company's strategic expansion into four European markets, Japanese regulatory approval and BioIntelliSense partnership demonstrate successful geographical and technological diversification. The implementation of manufacturing automation for Zio monitor should drive margin improvements through operational efficiencies. The focus on primary care channels and risk-bearing entities indicates a clear path to market share expansion in the
The clinical validation through five American Heart Association studies strengthens Zio's market position, particularly highlighting its effectiveness in early arrhythmia detection for high-risk populations with type 2 diabetes and respiratory conditions. The FDA clearances for Zio AT device enhancements demonstrate continued product innovation and regulatory execution.
The successful deployment of Epic Aura integration across four healthcare systems is a game-changing development that will accelerate adoption in 2025. The home enrollment capability for Zio monitor represents a significant competitive advantage in the remote monitoring space. The 2 million+ patient milestone validates the platform's scalability and clinical utility, while the focus on population health management aligns perfectly with value-based care trends.
The market's response to IRTC's operational execution warrants attention, particularly given the company's
The strategic focus on quality systems enhancement and international market penetration in 2025 addresses both defensive and growth aspects of the business model. The BioIntelliSense partnership opens new market opportunities through technology licensing, while manufacturing automation should support scaling operations efficiently. These developments position IRTC favorably against competitors in the rapidly growing cardiac monitoring market.
SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 43rd Annual J.P. Morgan Healthcare Conference.
Recent Operational Highlights and Financial Outlook
- Anticipate full year 2024 revenue slightly above high end of previously stated guidance range of
$587.5 million provided in October 2024 - Record quarter of new account openings for both Zio monitor and Zio AT during the fourth quarter 2024 as well as strong volume contributions from large national accounts
- Launched first four health care systems on Epic Aura during the fourth quarter 2024 with broad commercial roll out for Epic health systems across the U.S. beginning in 2025
- Initiated Zio monitor shipments for home enrollment patients during the fourth quarter 2024
- Five studies presented at the American Heart Association highlight Zio Monitor’s high patient satisfaction, engagement and compliance with the patient MyZio app and digital tools, health economic impact of early arrhythmia detection in type 2 diabetes and respiratory disease, and AI insights on sleep and activity patterns1
- Expect revenue for the full year 2025 of approximately
$675 million to$685 million
“This past year was a period of significant growth and transformation for iRhythm,” said Quentin Blackford, iRhythm’s President and CEO. “In our core U.S. business, we achieved a record number of Zio registrations from across different channels – serving over 2 million patients, advancing Zio utilization earlier in the patient care pathway, and growing our market penetration within ambulatory cardiac monitoring. Notably, we secured FDA clearance for two 510(k) submissions related to our Zio AT device, further advancing our technology for the benefit of patients, physicians, and healthcare systems who rely on our Zio AT services. To enable future growth on a global scale, we also expanded into four European countries, earned Japanese regulatory approval, signed a strategic technology licensing agreement with BioIntelliSense, and launched the initial phase of manufacturing automation for Zio monitor. Lastly, we implemented several sustainable operational efficiencies throughout the business, driving profitability expansion and positioning us to continue to grow efficiently into the future.”
“With this strong foundation of execution in 2024, we are well positioned to continue transforming iRhythm through a commitment to excellence, innovation, and value creation,” Blackford continued. “In 2025, our top priority will be on ensuring that our quality systems are best-in-class. Commercially, we plan to expand further into primary care channels through our land-and-expand strategy and by continuing to drive momentum within risk-bearing entities as Zio becomes a key tool in population health management. Internationally, we are also excited to drive further penetration within international markets where we are earlier in the commercial adoption curve. With our recent achievements and the opportunities ahead, we remain focused on delivering sustainable value for patients, clinicians, healthcare systems, and shareholders,” concluded Mr. Blackford.
Webcast and Conference Presentation Information
At the upcoming 43rd Annual J.P. Morgan Healthcare Conference, iRhythm’s management is scheduled to present on Monday, January 13, 2025, at 7:30 p.m. Eastern Time/4:30 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats2 into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all. To learn more about iRhythm, including its portfolio of Zio products and services, please visit irhythmtech.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future actions or operating or financial performance. In particular, these statements include statements regarding financial guidance, market opportunity, ability to penetrate the market, anticipated productivity and quality improvements and expectations for growth. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including those in iRhythm’s most recent filings on Form 10-K, Form 10-Q and other SEC filings, all of which are available on iRhythm’s website. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.
Investor Contact
Stephanie Zhadkevich
investors@irhythmtech.com
Media Contact
Kassandra Perry
irhythm@highwirepr.com
- The accelerometer data and the sleep and activity classification algorithm presented at AHA in November 2024 are intended exclusively for research purposes and are not available for any commercial use.
- Based on the US and UK data using Zio ECG monitors. Data on file. iRhythm Technologies, 2025.
FAQ
What is iRhythm's (IRTC) revenue guidance for 2025?
How did IRTC perform against its 2024 revenue guidance?
What major operational milestones did IRTC achieve in Q4 2024?
What international expansion did IRTC accomplish in 2024?
How many patients did IRTC serve with Zio registrations in 2024?
